The small intestine accounts for 75% of the length and 90% of the absorptive surface of the gastrointestinal tract. Fortunately, despite the large surface area, the incidence of malignant small bowel tumours is low and makes up \<5% of all gastrointestinal tumours ([@bib34]; [@bib36]; [@bib3]). Small bowel adenocarcinoma (SBA) is one of the most common histological subtypes that accounts for ∼40% of malignant small bowel tumours ([@bib4]). According to the EUROCARE data, the incidence of SBA is estimated at ∼3600 new cases per year in Europe ([@bib13]).

Surgical resection with regional lymph node dissection is considered the standard therapy for localised and resectable disease. Long-term survival can be expected if curative resection is possible, but curative resection is often not feasible in patients with SBA, as this cancer is difficult to detect in the early stages of disease, and most cases are diagnosed in the advanced stage ([@bib11]). Although some reports have identified a survival benefit of systemic chemotherapy for patients with advanced SBA, its treatment outcome is not sufficient ([@bib36]; [@bib48]; [@bib3]). Therefore, the prognosis of all stages remains poor and the 5-year overall survival (OS) rate is ∼30%, with a median OS time of ∼19 months ([@bib3]). Several studies have investigated the prognostic factors of SBA. These have identified advanced age, poorly differentiated carcinoma, T4 tumour stage, and duodenal primary site as important prognostic factors ([@bib22]; [@bib44]; [@bib11]; [@bib14]; [@bib46]; [@bib4]; [@bib21]; [@bib19]; [@bib48]; [@bib27]).

As primary adenocarcinoma of the small intestine is rare, most previous studies were retrospective and conducted in single tertiary care centres. Data of these studies were potentially limited by selection bias, and may not accurately reflect true SBA status. On the other hand, some registry database studies, with large data sets and reduced risk of selection bias, have been conducted; however, they may lack detailed data. In this study, we conducted a multicentre observational study to clarify the clinical characteristics, current status, prognostic factors, and outcome of primary SBA.

Materials and methods
=====================

Patients
--------

This multicentre retrospective study included a total of 205 patients who were diagnosed with adenocarcinoma of the small intestine at the following 11 hospitals from June 2002 and August 2013: Okayama University Hospital, Kurashiki Central Hospital, Okayama Saiseikai General Hospital, Hiroshima City Hiroshima Citizens Hospital, Shikoku Cancer Center, Japanese Red Cross Okayama Hospital, Kagawa Prefectural Hospital, Mitoyo General Hospital, Japanese Red Cross Society Himeji Hospital, Tsuyama Chuo Hospital, and Sumitomo Besshi Hospital. Patient data were collected after approval by the institutional review boards of each hospital.

Data collection
---------------

Data of patients with small intestinal tumours with a histological diagnosis of adenocarcinoma were included in this study. Exclusion criteria were: (1) tumour located on ampulla of Vater, (2) suspected invasive tumour of the pancreas, and (3) small intestinal metastasis from the cancer of other organs. Patients' medical records were reviewed and the following clinicopathologic parameters were collected: gender, age, Eastern Cooperative Oncology Group Performance Status (ECOG PS), site of primary tumour, predisposing conditions, histological type, symptoms at diagnosis, Union for International Cancer Control (7th edn) cancer stage based on the tumour, nodes, metastasis (TNM) classification, blood examination dates (carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), haemoglobin (Hb), neutrophil-to-lymphocyte rate (NLR), platelet (Plt), alanine aminotransferase, creatinine, lactate dehydrogenase (LDH), albumin (Alb), sodium), treatment, and survival. We investigated the clinical features, OS, and prognostic factors.

Statistical analysis
--------------------

All continuous variables are reported as median (range), and all categorical variables are summarised as frequencies (percentages). The Wilcoxon's rank-sum test was used to compare continuous variables. The *χ*^2^ test or Fisher's exact test was used to compare categorical variables. Overall survival was estimated by the Kaplan--Meier method and the difference was evaluated using the log-rank test. Cox proportional hazard model was used to identify independent prognostic factors for OS. All tests were two-sided, and a *P*-value under 0.05 was considered statistically significant. Statistical analyses were performed using JMP 11 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patient characteristics
-----------------------

Two-hundred and five patients from the 11 institutions were included. Patient characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. Median age was 68 years (range, 29--89), and 147 patients (71.7%) were men. Only three patients had predisposing conditions: one patient had familial adenomatous polyposis (FAP), one patient had Crohn's disease, and one patient had Lynch syndrome.

The location of the primary tumour was in the duodenum and jejunoileum in 149 (72.7%) and 56 (27.3%) patients, respectively. The histological type was undifferentiated in 39 patients; these patients accounted for ∼20% of the study cohort.

At the time of diagnosis, 127 patients (62.0%) were symptomatic. We defined intestinal stenosis-related symptoms as abdominal pain or vomiting, and bleeding-related symptoms as melena and anaemia secondary to tumour haemorrhage. The clinical presentation included stenosis-related symptoms in 65 (31.7%) and bleeding-related symptoms in 52 (25.4%) patients. Among patients with duodenal adenocarcinoma, 64 (43.0%) were asymptomatic at diagnosis. This is in contrast with the 47 patients (83.9%) with jejunoileal adenocarcinoma who were symptomatic at the time of diagnosis (*P*=0.0002). Among asymptomatic patients, 85.9% (55 out of 64) with duodenal carcinoma were incidentally diagnosed by oesophagogastroduodenoscopy (EGD), which was not specifically performed for the detection or surveillance of duodenal tumours. Five of nine (55.6%) cases of jejunoileal carcinoma were detected by computed tomography, which was performed due to abdominal surgery in four patients and a personal request in one patient.

TNM stages were as follows: 62 (41.6%), 20 (13.4%), 36 (24.2%), and 31 (20.8%) patients with stage 0/I, II, III, and IV duodenal adenocarcinoma, respectively, and 6 (10.7%), 14 (25.0%), 13 (23.2%), and 23 (41.1%) with jejunoileal adenocarcinoma, respectively. Among patients with stage IV disease, the liver and the peritoneum were the most common initial sites of metastatic disease; liver metastasis and peritoneal metastases were present in 27 patients and lung metastases were present in 9 patients.

OS and prognostic factors
-------------------------

The median follow-up period was 26.7 months (range, 0.2--148.9 months). Eighty-nine patients were followed until death and 115 patients survived during the follow-up period. [Figure 1](#fig1){ref-type="fig"} shows the complement of the Kaplan--Meier curves for TNM staging. The 3-year survival rate for stage 0/I, II, III, and IV disease was 93.4%, 73.1%, 50.9%, and 15.1%, respectively. As the tumour stage advanced, the survival rate progressively decreased.

[Table 2](#tbl2){ref-type="table"} shows the prognostic factors in each stage (stage 0/I and II, stage III, and stage IV) determined by univariate analysis. In stage 0/I and II, age (\>68 years), ECOG PS (3--4), undifferentiated type, Hb (\<12.5 g dl^−1^), Alb (\<3.8 g dl^−1^), and symptomatic at diagnosis were prognostic factors for OS. In stage III, male, NLR (⩾3.0), and Plt (2.5 × 10^4^/μl^−1^) were prognostic factors for OS. In stage IV, age (\>68 years), ECOG PS (3--4), CEA (\>5.0 mg ml^−1^), and Alb (\<3.8 g dl^−1^) were prognostic factors. Although not statistically significant, primary site of tumour (duodenum) and LDH (\>240 U l^−1^) tended to be associated with a worse prognosis in stage III.

Univariate and multivariate analyses were conducted to identify independent prognostic factors for OS; the results of these analyses are shown in [Table 3](#tbl3){ref-type="table"}. Univariate analysis revealed the following factors were significantly associated with poor OS: age \>68 years, poor ECOG-PS (3--4), undifferentiated type, high CEA (\>5.0 ng ml^−1^), high CA19-9 (\>37 U ml^−1^), high NLR (⩾3.0), high LDH (\>240 U l^−1^), low Alb (\<3.8 g dl^−1^), symptomatic at diagnosis, and progression of TNM stage. Multivariate analysis showed PS 3--4 (hazard ratio (HR): 2.26; 95% confidence interval (CI): 1.06--4.60; *P*=0.035), high CEA (HR: 1.88; 95% CI: 1.09--3.22; *P*=0.024), high LDH (HR: 2.50; 95% CI: 1.23--4.90; *P*=0.012), low Alb (HR: 1.99; 95% CI:1.11--3.59; *P*=0.020), symptomatic (HR: 2.27; 95% CI: 1.03--5.34; *P*=0.042), and stage III and IV (HR: 2.96; 95% CI: 1.52--6.16; *P*=0.001) were independent prognostic factors for OS.

Treatment modality and survival of stage IV patients
----------------------------------------------------

Among 54 patients with stage IV disease, 25 patients (46.3%) underwent resection of the primary tumour, 33 (61.1%) received systemic chemotherapy, and 11 (20.4%) underwent local treatment for distant metastasis such as resection or radiofrequency ablation.

We defined the combined modality therapy group as patients who received all of the following: primary resection, chemotherapy, and local treatment for distant metastasis; the chemotherapy-alone group was defined as those patients who received only chemotherapy for the treatment of metastatic lesions; and the best supportive care (BSC) group was defined as patients who did not receive chemotherapy.

Based on these definitions, 10 patients (18.5%) were included in the combined modality therapy group, 23 patients (43.3%) in the chemotherapy-alone group, and 21 patients (38.9%) in the BSC group.

[Table 4](#tbl4){ref-type="table"} shows the comparison of the clinical characteristics of stage IV patients by treatment group. Kaplan--Meier curves of OS by treatment group are shown in [Figure 2](#fig2){ref-type="fig"}. The median OS for the combined modality therapy group, chemotherapy group, and BSC group was 36.9, 12.3, and 5.9 months, respectively. The OS of the combined modality therapy group was significantly longer than that of the other therapy groups (HR: 0.27; 95% CI: 0.09--0.65; *P*=0.0021).

Discussion
==========

In this retrospective, multicentre, observational study, we enrolled more than 200 SBA patients at 11 institutions and investigated them in detail. Most previous studies followed a single-centre retrospective design, which were likely limited by selection bias. Although there are several large-scale studies involving data from registry databases, the clinical data may have lacked sufficient detail. We expected our multicentre study to have a lower risk of selection bias than in a single-centre study and our findings likely reflect the current clinical status. We collected detailed data including data that have not been examined before. As a result, we obtained some new findings.

In this study, primary SBA was most common in men in their 60s, and was located in the duodenum in 72.7% of patients. The incidence of undifferentiated adenocarcinoma was 19.0%. Although the patients' characteristics in the current study were similar to previous studies ([@bib34]; [@bib11]; [@bib46]; [@bib36]; [@bib48]; [@bib3]), some new knowledge was gained.

Most SBA patients are diagnosed after symptom onset. Common presenting symptoms of SBA include stenosis-related symptoms such as abdominal pain or vomiting, and bleeding-related symptoms. However, stenosis-related symptoms are rarely identified in early SBA patients, because the small intestinal products are liquid and, therefore, less likely to obstruct. As a result, most SBA patients are diagnosed with advanced disease ([@bib44]; [@bib11]; [@bib5]; [@bib21]; [@bib19]). In this study, when focusing only on duodenal adenocarcinoma, ∼40% of patients were diagnosed with asymptomatic, early-stage disease. These patients were diagnosed incidentally by screening via EGD, which is widely performed in Japan, as directed by the national healthcare system, for detection of gastric cancer. EGD allows for the visualisation of the intestinal tract up to the third portion of the duodenum. Considering the low prevalence of SBA, EGD for the detection of duodenal cancer may not be a reasonable approach. However, our findings suggest that when EGD is performed, regardless of the reason, observing the duodenum with the intention of detecting duodenal cancer is recommended. Alternatively, more than 80% of the patients with jeunoileal adenocarcinoma were symptomatic at the time of diagnosis, and most of them had progressive disease.

Crohn's disease, FAP, Lynch syndrome, Peutz-Jeghers syndrome, and celiac disease are known predisposing conditions of SBA ([@bib18]; [@bib28]; [@bib17]; [@bib16]; [@bib24]; [@bib41]; [@bib40]). Recently, earlier detection of jejunoileal cancer has been possible due to technical progress in enteroscopic techniques including video capsule endoscopy (VCE) and balloon-assisted enteroscopy. The usefulness of VCE for the detection of small bowel tumours has been reported ([@bib7], [@bib6]; [@bib39]). However, in this study, there were few patients with those predisposing conditions. Given the low prevalence of SBA and the invasiveness and cost of enteroscopy, screening enteroscopy for patients without predisposing conditions is not rational. Therefore, it is crucial to identify other high-risk predisposing factors that can be easily and less invasively detected.

Previous studies have revealed that advanced age, tumour markers (CEA, CA19-9), primary site in duodenum, poorly differentiated carcinoma, pT4 tumour stage, positive resection margins, positive lymphovascular invasion, number of lymph node metastasis, resection of primary tumour, low Alb, and abnormal Plts were poor prognostic factors in SBA patients ([@bib22]; [@bib44]; [@bib11]; [@bib14]; [@bib46]; [@bib1]; [@bib38], [@bib37]; [@bib4]; [@bib21]; [@bib19]; [@bib48]; [@bib27]). In the current study, ECOG PS 3--4, high CEA, high LDH, low Alb, symptomatic at diagnosis, and stages III and IV were found to be independent prognostic factors for OS. Our results were similar to previous studies, but our study also identified high LDH and symptomatic at diagnosis as novel prognostic factors. These factors have not been sufficiently considered in previous studies. LDH is a metabolic enzyme that catalyzes the conversion of lactate to pyruvate, and high LDH is a well-known poor prognostic factor in patients with various malignancies ([@bib50]; [@bib29]). Similar to other malignancies, evaluation of serum LDH might be useful to predict prognosis in SBA patients. Given the limited number of asymptomatic patients with SBA, previous studies have not investigated the effect of the presence or absence of symptoms on disease prognosis. In our study, 69 patients (34.5%) were asymptomatic at diagnosis. Therefore, we were able to identify the presence of symptoms at diagnosis as an independent prognostic factor.

Some studies reported that duodenal carcinoma has a worse prognosis than jejunoileal carcinoma ([@bib22]; [@bib11]; [@bib37]; [@bib27]), and others reported that the primary site of tumour was not associated with the prognosis ([@bib44]; [@bib46]; [@bib1]; [@bib38]; [@bib21]; [@bib19]; [@bib48]). In the current study, patients with duodenal carcinoma were detected in an earlier stage compared with jejunoileal carcinoma. However, primary site was not a significant prognostic factor, which finding may have been affected by the results of stage III patients. While not significant, there was a tendency towards worse OS in duodenal carcinoma in stage III. One reason for this tendency may be the invasiveness of the radical resection of the duodenal carcinoma affected the result (i.e., pancreatoduodenectomy).

Univariate analysis by each stage revealed that prognostic factors (e.g., PS, Alb) in stage 0/I and II patients related to the patient's general condition, suggesting that tumour factors were not involved in the prognosis at an early stage. In stage III, LDH (\>240 U l^−1^) tended to be associated with a worse prognosis, although there was insufficient statistical power to detect this association, because of the small number of patients. However, even without distant metastasis, LDH may be considered a prognostic factor reflecting the tumour burden when the tumour becomes a locally advanced stage.

Several studies have confirmed the survival benefit of chemotherapy for patients with advanced SBA ([@bib35]; [@bib25]; [@bib9]; [@bib11]; [@bib30]; [@bib14]; [@bib38]; [@bib48], [@bib49]; [@bib19]; [@bib45]; [@bib31]). However, despite advances in treatment, the prognosis remains poor. Previous studies reported the OS of advanced SBA patients who received systemic chemotherapy was ∼10--20 months ([@bib30]; [@bib38]; [@bib48], [@bib49]; [@bib45]). In this study, combined modality therapy was only applicable to patients who were young, with good nutritional status, and with resectable metastatic lesions. Furthermore, the number of patients who underwent combined modality therapy in this study was small. Therefore, it is difficult to make direct comparisons with the other treatment groups. However, the OS of 36.9 months in the combined modality therapy group was clearly long, highlighting the benefit of this treatment protocol. Some studies reported that the biological characteristics of SBA are similar to those of colorectal carcinoma ([@bib1]; [@bib10]; [@bib2]), and that the chemotherapy regimen used to treat colorectal carcinoma can be applied to the treatment of SBA. In colorectal carcinoma, combined modality therapy, including resection of the liver and lung metastasis, is the standard therapy for resectable disease ([@bib15]; [@bib8]; [@bib12]; [@bib32]; [@bib26], [@bib29]; [@bib47]; [@bib33]; [@bib42]; [@bib20]; [@bib23]), and this approach may be appropriate for SBA. The usefulness of combined modality therapy, including local treatment of resectable metastasis, has not been assessed in previous studies. Therefore, the results of this study might help direct future research related to treatment strategies for advanced SBA.

This study has several limitations. First, this is a retrospective study; however, considering the rarity of SBA, the retrospective analysis should be acceptable. Second, patients with Lynch syndrome may be under-represented because family history data was not collected, which likely resulted in an underestimation of patients with predisposing conditions. Third, combined modality therapy was limited to patients whose metastatic lesions were feasible for local treatment; therefore, some selection bias and institutional bias are present. However, when combined modality therapy was feasible, long-term survival was possible.

Conclusions
===========

The results of this study suggest that when EGD is performed, regardless of the reason, observing the duodenum with the intention of detecting duodenal cancer is recommended. We found ECOG PS 3--4, high CEA, high LDH, low Alb, symptomatic at diagnosis, and stage III and IV were independent prognostic factors for OS. Although the prognosis of advanced SBA was poor, combined modality therapy, including local treatment of distant metastasis, may prolong patient survival.
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![**Kaplan--Meier curves of OS by TNM stage.**](bjc2017338f1){#fig1}

![**Kaplan--Meier curves of OS for stage IV patients by treatment.** Combined modality therapy group refers to patients who received primary resection, chemotherapy, and local treatment for distant metastasis; the chemotherapy-alone group refers to patients who received only chemotherapy; and the BSC group refers to patients who did not receive chemotherapy. The OS of the combined modality therapy group was significantly longer than that of the other therapy groups (HR: 0.27; 95% CI: 0.09--0.65; *P*=0.0021).](bjc2017338f2){#fig2}

###### Patient characteristics

                                                **All,** ***n*****=205**   **Duodenum,** ***n*****=149**   **Jejunoileum,** ***n*****=56**   ***P*****-value**
  --------------------------------------------- -------------------------- ------------------------------- --------------------------------- -------------------
  **Gender, *n* (%)**                                                                                                                        
  Male                                          147 (71.7)                 110 (73.8)                      37 (66.1)                         0.28
  Female                                        58 (28.3)                  39 (26.2)                       19 (33.9)                          
  Age, median (range)                           68(29--89)                 68 (29--89)                     66.5 (29--87)                     0.31
  **Predisposing conditions, *n***                                                                                                           
  None                                          202                        149                             53                                 
  FAP                                           1                          0                               1                                  
  Crohn's disease                               1                          0                               1                                  
  Linch syndrome                                1                          0                               1                                  
  **Histological type, *n* (%)**                                                                                                             
  Differentiated                                163 (79.5)                 117 (78.5)                      46 (82.1)                         0.68
  Undifferentiated                              39 (19.0)                  30 (20.1)                       9 (16.1)                           
  Unknown                                       3 (1.5)                    2 (1.4)                         1 (1.8)                            
  **Symptom at diagnosis, *n* (%)**                                                                                                          
  Symptomatic                                   128 (62.4)                 81(53.7)                        47(83.9)                          0.0002
  Stenosis-related[a](#t1-fn2){ref-type="fn"}   65                         34                              31                                 
  Bleeding-related[a](#t1-fn2){ref-type="fn"}   52                         32                              20                                 
  Others                                        33                         27                              6                                  
  Asymptomatic                                  73(35.6)                   64 (43.0)                       9 (16.1)                           
  Unknown                                       4 (2.0)                    4 (2.7)                         0 (0.0)                            
  **TNM stage, *n* (%)**                                                                                                                     
  Stage 0/I                                     68 (33.2)                  62 (41.6)                       6 (10.7)                          0.0001
  Stage II                                      34 (16.6)                  20 (13.4)                       14 (25.0)                          
  Stage III                                     49 (23.9)                  36 (24.2)                       13 (23.2)                          
  Stage IV                                      54 (26.3)                  31 (20.8)                       23 (41.1)                          
  **Site of distant metastasis**                                                                                                             
  (Liver/peritoneum/lung/others)                27/27/9/11                 16/12/3/7                       11/15/6/4                          

Abbreviations: FAP=familial adenomatosis polyposis; TNM=tumour node metastases.

There is some overlapping.

###### Univariate analysis for overall survival in each stage (stage 0/I and II, stage III, stage IV)

                                                **Stage 0/I/II,** ***n*****=102**   **Stage III,** ***n*****=49**   **Stage IV,** ***n*****=54**                                                    
  --------------------------------------------- ----------------------------------- ------------------------------- ------------------------------ ------ ------------ ------- ------ ------------- --------
  Gender (male)                                 1.44                                0.47--6.21                      0.55                           2.77   1.14--8.28   0.023   0.74   0.38--1.51    0.38
  Age (\>68 years)                              3.58                                1.34--11.21                     0.010                          1.08   0.52--2.25   0.83    2.57   1.37--4.81    0.0036
  ECOG PS (3--4)                                9.30                                2.03--31.92                     0.0072                         1.67   0.49--4.35   0.38    4.85   1.82--11.79   0.0026
  Primary site of tumour (duodenum)             1.63                                0.52--4.39                      0.38                           2.35   0.98--6.98   0.058   1.27   0.68--2.40    0.45
  Histological type (undifferentiated)          4.77                                1.49--12.99                     0.011                          1.28   0.58--2.70   0.53    1.97   0.87--4.09    0.10
  CEA (\>5.0 ng ml^−1^)                         1.32                                0.37--3.69                      0.64                           1.88   0.35--34.8   0.51    2.83   1.44--5.75    0.0026
  CA19-9 (\>37 U ml^−1^)                        1.33                                0.27--23.99                     0.78                           2.00   0.91--4.36   0.084   1.52   0.80--2.92    0.21
  NLR (⩾3.0)                                    0.95                                0.21--3.03                      0.93                           2.46   1.18--5.33   0.017   1.13   0.59--2.12    0.89
  Hb (\<12.5 g dl^−1^)                          3.18                                1.21--8.83                      0.019                          1.88   0.89--4.23   0.099   1.21   0.65--2.30    0.54
  Plt (\>25 × 10^4^/μl)                         1.99                                0.78--5.25                      0.15                           2.30   1.06--5.09   0.035   0.97   0.52--1.82    0.93
  ALT (\>45 U l^−1^)                            0.94                                0.05--4.64                      0.95                           1.42   0.48--3.45   0.49    0.67   0.19--1.71    0.43
  Cr (\>1.1 mg dl^−1^)                          1.98                                0.46--6.08                      0.32                           1.30   0.21--4.53   0.73    1.65   0.56--3.89    0.33
  LDH (\>240 U l^−1^)                           1.37                                0.22--4.90                      0.69                           2.56   0.99--5.92   0.052   1.11   0.45--2.36    0.81
  Alb (\<3.8 g dl^−1^)                          7.40                                2.82--20.55                     \<0.0001                       1.60   0.76--3.40   0.21    2.05   1.10--3.87    0.025
  Na (\<140 mEq l^−1^)                          0.89                                0.31--2.29                      0.81                           1.37   0.66--2.83   0.39    1.51   0.81--2.91    0.20
  Symptoms present at diagnosis (symptomatic)   4.40                                1.59--14.01                     0.004                          1.31   0.54--3.93   0.58    1.08   0.46--3.15    0.88

Abbreviations: Alb=albumin; ALT=alanine aminotransferase; CA 19-9=carbohydrate antigen 19-9; CEA=carcinoembryonic antigen; Cr=creatinine; ECOG PS=Eastern Cooperative Oncology Group Performance Status; Hb=haemoglobin; LDH=lactate dehydrogenase; Na=sodium; NLR=neutrophil-to-lymphocyte ratio; Plt=platelet.

###### Univariate and multivariate analysis for OS

                                                **Univariate analysis for OS**    **Multivariate analysis for OS**                                 
  --------------------------------------------- -------------------------------- ---------------------------------- ---------- ------ ------------ -------
  Gender (male)                                 1.13                                         0.70--1.88             0.63                            
  Age (\>68 years)                              1.58                                         1.04--2.40             0.032      1.39    0.82--2.36  0.22
  ECOG PS (3--4)                                3.77                                         2.02--6.54             0.0001     2.26    1.06--4.60  0.035
  Primary site of tumour (duodenum)             1.21                                         0.76--1.88             0.41                            
  Histological type (undifferentiated)          2.92                                         1.81--4.59             \<0.0001   1.82    0.98--3.32  0.057
  CEA (\>5.0 ng ml^−1^)                         2.26                                         1.46--3.47             0.0003     1.88    1.09--3.22  0.024
  CA19-9 (\>37 U ml^−1^)                        2.78                                         1.75--4.33             \<0.0001   1.59    0.90--2.78  0.11
  NLR (⩾3.0)                                    2.06                                         1.33--3.23             0.0011     1.04    0.60--1.78  0.89
  Hb (\<12.5 g dl^−1^)                          2.21                                         1.45--3.42             0.0002     1.02    0.53--1.91  0.96
  Plt (\>25 × 10^4^/μl)                         1.17                                         0.77--1.78             0.45                            
  ALT (\>45 U l^−1^)                            1.35                                         0.66--2.48             0.39                            
  Cr (\>1.1 mg dl^−1^)                          1.35                                         0.65--2.48             0.40                            
  LDH (\>240 U l^−1^)                           1.92                                         1.08--3.23             0.028      2.50    1.23--4.90  0.012
  Alb (\<3.8 g dl^−1^)                          3.33                                         2.8--5.10              \<0.0001   1.99    1.11--3.59  0.020
  Na (\<140 mEq l^−1^)                          1.46                                         0.96--2.23             0.075                           
  Symptoms present at diagnosis (symptomatic)   4.15                                         2.47--7.42             \<0.0001   2.27    1.03--5.34  0.042
  Stage (III--IV)                               7.21                                        4.37--12.53             \<0.0001                        

Abbreviations: Alb=albumin; ALT=alanine aminotransferase; CA 19-9=carbohydrate antigen 19-9; CEA=carcinoembryonic antigen; Cr=creatinine; ECOG PS=Eastern Cooperative Oncology Group Performance Status; Hb=haemoglobin; LDH=lactate dehydrogenase; Na=sodium; NLR=neutrophil-to-lymphocyte ratio; Plt=platelet.

###### Clinical characteristics of stage IV patients by treatment group

                                        **All,** ***n*****=54**   **Combined modality therapy,** ***n*****=10**   **Chemotherapy alone,** ***n*****=23**   **BSC,** ***n*****=21**   ***P-value***
  ------------------------------------- ------------------------- ----------------------------------------------- ---------------------------------------- ------------------------- ---------------
  **Gender, *n* (%)**                                                                                                                                                                
  Male                                  37 (68.5)                 6 (60.0)                                        17 (73.9)                                14 (66.7)                 0.71
  Female                                17 (31.5)                 4 (40.0)                                        6 (26.1)                                 7 (33.3)                   
  Age, median (range)                   67.5 (29--87)             55.5 (31--73)                                   65 (29--83)                              77 (51--87)               0.0026
  **ECOG PS, *n* (%)**                                                                                                                                                               
  0--2                                  47 (87.0)                 10 (100.0)                                      19 (82.6)                                18 (85.7)                 0.38
  3--4                                  7 (13.0)                  0 (0.0)                                         4 (17.4)                                 3 (14.3)                   
  Body mass index, median (range)       20.6 (13.8--29.7)         21.3 (19.4--26.2)                               20.5 (14.7--28)                          20.1 (13.8--29.7)         0.44
  **Primary site of tumour, *n* (%)**                                                                                                                                                
  Duodenum                              32 (57.4)                 6 (60.0)                                        14 (60.9)                                11 (52.4)                 0.84
  Jejunum/ileum                         23 (42.6)                 4 (40.0)                                        9 (39.1)                                 10 (47.6)                  
  **Histological type, *n* (%)**                                                                                                                                                     
  Differentiated                        41 (77.4)                 8 (80.0)                                        16 (72.7)                                17 (80.9)                 0.64
  Undifferentiated                      11 (20.7)                 2 (20.0)                                        6 (27.3)                                 3 (14.3)                   
  Unknown                               1 (1.9)                                                                                                            1 (4.8)                    
  **Laboratory date, median (range)**                                                                                                                                                
  CEA (ng ml^−1^)                       5 (0.4--458)              2.9 (0.4--108.2)                                4.5 (0.7--458)                           6.1 (0.5--408)            0.16
  CA19-9 (U ml^−1^)                     24 (0.4--6259.6)          16.95 (1--5273.6)                               47.15 (3--6259.6)                        15.3 (0.4--4806.8)        0.18
  LDH (U l^−1^)                         177 (116--1077)           163 (145--288)                                  177 (116--1077)                          187 (122--313)            0.77
  Alb (g dl^−1^)                        3.8 (2.1--5.1)            4.2 (3.8--5.1)                                  4 (2.9--5.0)                             3.6 (2.1--4.4)            0.036

Abbreviations: Alb=albumin; CA 19-9=carbohydrate antigen 19-9; CEA=carcinoembryonic antigen; ECOG PS=Eastern Cooperative Oncology Group Performance Status; LDH=lactate dehydrogenase.
